Vogelxo is a drug owned by Upsher Smith Laboratories Llc. It is protected by 4 US drug patents filed from 2014 to 2017 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 11, 2034. Details of Vogelxo's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9622340 | Flexible circuit board and method for manufacturing same |
Feb, 2034
(8 years from now) | Active |
| US8785426 | Testosterone gel compositions and related methods |
Feb, 2034
(8 years from now) | Active |
| US9662340 | Testosterone gel compositions and related methods |
Feb, 2034
(8 years from now) | Active |
| US9295675 | Testosterone gel compositions and related methods |
Feb, 2034
(8 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Vogelxo's patents.
Latest Legal Activities on Vogelxo's Patents
Given below is the list of recent legal activities going on the following patents of Vogelxo.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 12 Jun, 2024 | US9662340 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 19 Aug, 2021 | US8785426 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 Sep, 2020 | US9622340 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 04 Jun, 2020 | US9662340 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 12 Oct, 2017 | US8785426 |
| Patent Issue Date Used in PTA Calculation Critical | 30 May, 2017 | US9662340 |
| Recordation of Patent Grant Mailed Critical | 30 May, 2017 | US9662340 |
| Email Notification Critical | 11 May, 2017 | US9662340 |
| Issue Notification Mailed Critical | 10 May, 2017 | US9662340 |
| Dispatch to FDC | 03 May, 2017 | US9662340 |
FDA has granted several exclusivities to Vogelxo. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Vogelxo, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Vogelxo.
Exclusivity Information
Vogelxo holds 1 exclusivities. All of its exclusivities have expired in 2017. Details of Vogelxo's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 04, 2017 |
US patents provide insights into the exclusivity only within the United States, but Vogelxo is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Vogelxo's family patents as well as insights into ongoing legal events on those patents.
Vogelxo's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Vogelxo's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Feb 11, 2034 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Vogelxo Generic API suppliers:
Testosterone is the generic name for the brand Vogelxo. 15 different companies have already filed for the generic of Vogelxo, with Actavis Labs Ut Inc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Vogelxo's generic
Alternative Brands for Vogelxo
Vogelxo which is used for delivering testosterone through the skin., has several other brand drugs using the same active ingredient (Testosterone). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |||
|---|---|---|---|---|
| Acerus |
| |||
| Alza |
| |||
| Antares Pharma Inc |
| |||
| Auxilium Pharms Llc |
| |||
| Azurity |
| |||
| Besins Hlthcare |
| |||
| Eli Lilly And Co |
| |||
| Endo Operations |
| |||
| Marius Pharms Llc |
| |||
| Tolmar |
| |||
| Verity |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Testosterone, Vogelxo's active ingredient. Check the complete list of approved generic manufacturers for Vogelxo
About Vogelxo
Vogelxo is a drug owned by Upsher Smith Laboratories Llc. It is used for delivering testosterone through the skin. Vogelxo uses Testosterone as an active ingredient. Vogelxo was launched by Upsher Smith Labs in 2014.
Approval Date:
Vogelxo was approved by FDA for market use on 04 June, 2014.
Active Ingredient:
Vogelxo uses Testosterone as the active ingredient. Check out other Drugs and Companies using Testosterone ingredient
Treatment:
Vogelxo is used for delivering testosterone through the skin.
Dosage:
Vogelxo is available in the following dosage forms - gel form for transdermal use, gel, metered form for transdermal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 12.5MG/1.25GM ACTUATION | GEL, METERED | Prescription | TRANSDERMAL |
| 50MG/5GM PACKET | GEL | Prescription | TRANSDERMAL |